Financials in GBp. Standardized financial statements.
A compact view of how MGC Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £3.39M | £4.73M | £3.00M | £2.08M | £656,237 | £296,811 | £120,242 | £2,197 | £0 | £11,357 |
| Revenue Growth? | -28.4% | +57.9% | +44.1% | +216.8% | +121.1% | +146.8% | +5373.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | £2.10M | £4.17M | £1.90M | £1.91M | £356,642 | £119,340 | £158,073 | £15,011 | £0 | £0 |
| Gross Profit? | £1.29M | £562,868 | £1.10M | £174,664 | £299,595 | £177,471 | -£37,831 | -£12,814 | £0 | £11,357 |
| Gross Margin? | +38.0% | +11.9% | +36.7% | +8.4% | +45.7% | +59.8% | -31.5% | -583.2% | 0.0% | +100.0% |
| Operating Expenses? | £17.05M | £16.07M | £16.64M | £11.98M | £9.34M | £9.26M | £8.57M | £6.14M | £3.80M | £5.35M |
| Operating Income? | -£15.23M | -£15.50M | -£11.94M | -£11.29M | -£8.71M | -£7.05M | -£7.29M | -£4.22M | -£3.63M | -£5.33M |
| EBITDA? | -£20.12M | -£15.16M | -£15.04M | -£18.15M | -£10.76M | -£8.54M | -£8.40M | -£6.09M | -£853,000 | -£500,000 |
| Income Before Tax | -£21.13M | -£20.77M | -£15.90M | -£18.77M | -£1.88M | -£8.99M | -£8.50M | -£6.23M | -£3.80M | -£5.34M |
| Income Tax Expense | £2,017 | -£420,000 | -£27,278 | -£7,137 | £27,315 | -£1,038 | -£358,000 | -£72,919 | £0 | £0 |
| Net Income? | -£20.82M | -£20.35M | -£15.87M | -£18.76M | -£11.01M | -£8.25M | -£8.14M | -£6.16M | -£3.80M | -£5.34M |
| EPS? | £-7.10 | £-7.90 | £-8.30 | £-14.00 | £-9.11 | £-7.33 | £-8.43 | £-10.20 | £-13.43 | £-33.40 |
| Diluted EPS? | £-7.07 | £-7.90 | £-8.30 | £-14.00 | £-9.11 | £-7.33 | £-8.43 | £-10.20 | £-13.43 | £-33.37 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality